T1	Claim 1 185	In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability.
T3	Premise 755 916	After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale.
T4	Premise 917 1172	Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.
T5	Claim 1173 1246	A steady improvement in quality of life was also observed in both groups.
T6	Premise 1247 1315	There were no clinically significant differences between the groups.
T7	Premise 1316 1559	In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy.
T8	Premise 1560 1682	Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).
T9	Claim 1716 1833	paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.
T2	Claim 186 252	Prompt diagnosis and effective treatment is, therefore, essential.
R1	Support Arg1:T3 Arg2:T9	
R2	Support Arg1:T6 Arg2:T9	
R3	Support Arg1:T7 Arg2:T9	
R4	Support Arg1:T5 Arg2:T9	
